Fallopian Tube Carcinosarcoma — Clinical Trials

MONDO:00062074 active·4 recruitingLast updated: Mar 20, 2026, 12:55 PM

Trial Landscape

Fallopian Tube Carcinosarcoma has an emerging clinical trial program, driven by procedure and biological therapy.

Recruiting

Active Trials

By Approach

Procedure4

Biological Therapy4

Drug Treatment3

1 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Sponsor Types

Academic/Other4

Trial Locations

United States4 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

4 Trials

Phase 2Recruiting

NCT06639074

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Sponsor:Mayo Clinic

United StatesStarted: Nov 2024Est. completion: Dec 2027Updated: Oct 2025

Phase 2Recruiting

NCT04919629

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: May 2025

Phase 1Recruiting

NCT06483048

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Sponsor:Mayo Clinic

United StatesStarted: Sep 2024Est. completion: Sep 2028Updated: Mar 2026

Phase 1Recruiting

NCT05920798

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Sponsor:Mayo Clinic

United StatesStarted: Sep 2023Est. completion: Jul 2027Updated: Jun 2025

Stay informed about clinical trials for Fallopian Tube Carcinosarcoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 12:55 PM

Fallopian Tube Carcinosarcoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

4 Trials

Open Trials4

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer